Expert Perspectives on the Latest Clinical Trial Updates in HR-Positive, HER2-Negative Early Breast Cancer

More options, more questions. Get clarity on patient selection and optimizing adjuvant cyclin-dependent kinase cyclin-dependent kinase (CDK)4/6 inhibitor therapy.

Credit available for this activity expires: 9/16/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002908?ecd=bdc_podcast_libsyn_mscpedu